FDA-approved breast cancer drug reduces risk of recurrence by 25%.

Novartis has announced that its breast cancer treatment Kisqali, already approved by the FDA for advanced stages of breast cancer, can reduce the risk of cancer coming back when added after primary treatment. The drug could be good news for women diagnosed in the earlier stages of the disease and those who are hormone-receptor positive and HER2 negative, who make up 70% of the breast cancer population. The findings were announced at the annual meeting of the American Society of Clinical Oncology, and Novartis plans to submit the data to regulatory authorities in the US and Europe before the end of the year.